Table 1

Demographic characteristics (intent-to-treat population)

Patient characteristicsPlacebo (N = 17)Sotagliflozin (N = 16)
Age (years), median (range)34.0 (21, 57)45.5 (21, 55)
Sex, n (%)
 Female9 (53)8 (50)
 Male8 (47)8 (50)
Race, n (%)
 White/Caucasian14 (82)16 (100)
 Asian2 (12)0
 Other1 (6)0
Weight (kg), median (range)72.7 (55.3, 104.6)74.2 (55.6, 107.9)
BMI (kg/m2), mean (SD)26.2 (3.0)27.1 (3.1)
Duration of diabetes (years), median (range)18.5 (4.7, 40.8)16.8 (3.4, 42.9)
HbA1c (%), mean (SD)7.98 (0.51)7.94 (0.55)
HbA1c (mmol/mol), mean (SD)62.83 (5.66)63.38 (6.04)
FPG (mmol/L), mean (SD)8.89 (3.96)9.45 (3.45)
Seated systolic BP (mmHg), mean (SD)119.8 (7.0)118.1 (9.2)
Serum sodium (mmol/L), mean (SD)138.24 (3.75)137.63 (2.45)
Serum creatinine (µmol/L), mean (SD)76.11 (9.86)76.94 (11.82)
Serum BUN (mmol/L), mean (SD)4.68 (0.99)4.96 (1.02)
Hematocrit, mean (SD)41.94 (4.87)41.63 (4.86)
Insulin therapy, n (%)
 MDI5 (29)6 (38)
 CSII12 (71)10 (63)
Total daily insulin (IU/kg), mean0.600.60
Daily insulin, ratio of bolus/total0.450.49
  • BP, blood pressure.